stsa-1002
mAbexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 28, 2021 (NCT05032144)
Timeline
Indications
Mechanism of action
C5AR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07208591 | Phase 3 | Oct 31, 2025 | Peking University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT06038916 | Phase 1/Phase 2 (Phase 2) | Dec 9, 2023 | Peking University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05702983 | Phase 1 | Jan 31, 2023 | Altasciences Company Inc., Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05559125 | Phase 1 | Nov 8, 2022 | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05497635 | Phase 1 | Oct 14, 2022 | Capital Medical University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05166837 | Phase 1 | Jan 10, 2022 | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05032144 | Phase 1 | Sep 28, 2021 | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals Co., Ltd | For profit | 7 | 7 | 3 | 2021 |
| Peking University | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Altasciences Company Inc. | For profit | 1 | 0 | 1 | 2023 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1